SLC5A2 and heart failure: Importantly, dedicated heart failure trials [7–9] demonstrated the efficacy of SGLT2 inhibitors in individuals who had heart failure with reduced ejection fraction (HFrEF), with and without type 2 diabetes, suggesting that the salutary effects of these agents are not confined to diabetic conditions.